BIO Statement on California’s Drug Price Reporting & Transparency Bill
September 13 2017 - 8:52PM
Business Wire
Biotechnology Innovation Organization (BIO) Senior Executive
Vice President for Public Affairs Gary Andres issued the following
statement regarding passage of a drug price reporting and
transparency bill (Senate Bill 17) within the California
Senate:
“Any legislative effort to address the affordability of
medicines must be patient centered, holistic, and promote patient
access to treatments and cures. Biotechnology innovation is not
only providing enormous benefits to patients and value to the
healthcare system, but it is a proven job creator, directly
employing over 242,000 Californians in good, high-paying jobs, with
billions invested in the state annually. Senate Bill 17 fails to
meet these tests and does not deliver on its purported
promises.
“BIO will continue to oppose legislative efforts, such as Senate
Bill 17, that harm patient access to needed care by undermining
competition, disrupting existing drug product availability, or
stifling investment in the innovation ecosystem through misguided
government intrusion.
“BIO encourages Governor Brown to weigh these important societal
and economic factors before signing legislation which poses such
significant threats to California's economy.”
About BIO
BIO is the world's largest trade association representing
biotechnology companies, academic institutions, state biotechnology
centers and related organizations across the United States and in
more than 30 other nations. BIO members are involved in the
research and development of innovative healthcare, agricultural,
industrial and environmental biotechnology products. BIO also
produces the BIO International Convention, the world’s largest
gathering of the biotechnology industry, along with
industry-leading investor and partnering meetings held around the
world. BIOtechNOW is BIO's blog chronicling “innovations
transforming our world” and the BIO Newsletter is the
organization’s bi-weekly email newsletter. Subscribe to the BIO
Newsletter.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170913006620/en/
Biotechnology Innovation Organization (BIO)George Goodno,
202-962-6660Web: www.bio.orgBlog: www.biotech-now.orgTwitter:
@IAmBiotech